

## Special Issue

# Polymeric Nanoparticles for Immunotherapy of Cancer

### Message from the Guest Editors

Cancer immunotherapeutics represents the cutting-edge alternative for an efficient treatment of many tumors. In recent years, advancements in the field have been huge, and cancer immunotherapy has currently become the standard of care for some tumors. However, for most internal tumors, although in vitro approximations of immunotherapy have demonstrated hints of success, their translation to in vivo is poor. This could be mainly attributed to the lack of efficient delivery systems that are required to ensure the required biodistribution. In this context, nanomedicine could represent a step forward for the application of immunotherapies in clinical practices. Polymeric nanoparticles have attracted increasing interest since their discovery thanks to the many advantages they represent for several biomedical applications. This Special Issue suggested topics are cancer therapeutic vaccines, adoptive cell transfer therapies, and checkpoint inhibitor therapies, provided that all of them make use of nanomedicine, specifically of polymeric nanoparticles, to deliver the active principle.

### Guest Editors

Dr. Cristina Fornaguera

Grup d'Enginyeria de Materials (GEMAT), Bioengineering Department, Institut Químic de Sarrià (IQS), School of Engineering, Universitat Ramon Llull (URL), Via Augusta 390, 08017 Barcelona, Spain

Dr. Marta Guerra-Rebollo

Grup d'Enginyeria de Materials (GEMAT), Bioengineering Department, Institut Químic de Sarrià (IQS), School of Engineering, Universitat Ramon Llull (URL), Via Augusta 390, 08017 Barcelona, Spain

### Deadline for manuscript submissions

closed (31 May 2022)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/104152](https://mdpi.com/si/104152)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).